[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immunoglobulin-deficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immunoglobulin-deficiency":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100484176",false,"NCT05584631","IVIG vs SCIG in CIDP","The Influence of Body Composition on Immunoglobulin Disposition After Intravenous and Subcutaneous Administration","Inclusion Criteria:\n\n* Patients aged \\>18 years with a current diagnosis of CIDP (based on European Federation of Neurological sciences \u002F Peripheral Nerve Society CIDP diagnostic criteria).\n* 1:1 conversion of IVIG to SCIG (weekly dose conversion) must fall within 0.2-to-0.4 mg\u002Fkg dose for SCIG.\n\nExclusion Criteria:\n\n* Patients receiving IVIG for indications other than CIDP will be excluded.\n* Patients with liver impairment (elevations in liver enzymes of greater than 3 times the upper limit of normal) or reduced renal function (CrCl \\\u003C 50 mL\u002Fmin) will be excluded\n* Active malignancies\n* Diabetes\n* Myasthenia gravis\n* Immunodeficiency\n* Autoimmune disease","ALL","18 Years","65 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.",[26,27,28],"CIDP","Immunoglobulin Deficiency","Chronic Inflammatory Demyelinating Polyneuropathy",[30,31,32],"immunoglobulin","pharmacokinetics","obesity","RECRUITING","2025-12-10",{"date":36,"type":37},"2025-12-11","ACTUAL",{"date":39,"type":37},"2022-09-11",{"date":41,"type":20},"2026-12-01",{"name":43,"class":44},"Rutgers, The State University of New Jersey","OTHER",""]